Jasper Therapeutics announces common stock offering, no amount given

Jasper Therapeutics (JSPR) announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock or, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in each case, together with accompanying common warrants to purchase shares of its common stock. Jasper intends to use the net proceeds from the proposed offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases, as well as for general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock, pre-funded warrants and common warrants to be sold in the proposed offering will be sold by Jasper. TD Cowen is acting as the sole book-running manager for the proposed offering.